Delphinus Raises $30 Million in Series D Funding to Transform Dense Breast Screening
Summary
DETROIT--(BUSINESS WIRE)-- Delphinus Medical Technologies, Inc. today announced the closing of a $30 million Series D financing to fuel worldwide commercialization of itsThis press release features multimedia. SoftVue enhances dense breast screening and identifies up to 20% more cancers with greater accuracy and potentially fewer biopsies than full field digital mammography (FFDM) alone. The SoftVue exam is completed with no compression or radiation, and its PMA indication for use allows SoftVue exams to be performed at the same appointment as screening mammograms, facilitating a streamlined workflow and rapid delivery of results.Our board of directors and investors are very excited to launch into commercial activities with SoftVue, said Paul McCreadie, Delphinus Medical Technologys board chairman and Partner and Chief Operating Officer at Arboretum Ventures. The successful completion of a rigorous clinical study that resulted in the PMA approval we received last year for dense breast screening will allow the Delphinus team to leverage the unique technology of SoftVue to change the paradigm for dense breast screening and help millions of women receive superior care. We invest to allow breakthrough innovations to serve patients, and Delphinus is perfectly poised to do exactly that.Headquartered in Novi, Mich., Delphinus Medical Technologies, Inc. is a pioneering medical imaging company that has developed SoftVue, featuring the first circular array transducer technology.